Revolutionizing Cancer Treatment: Oncology Expertise

Cancer, a complex and multifaceted disease that disrupts the body's normal cellular processes, afflicts millions worldwide. At Southern Research, we are dedicated to providing comprehensive preclinical oncological research and testing services, empowering researchers to unravel the intricacies of cancer biology and develop life-saving therapies.

SR-Oncology-Hero-1

Novel Cancer Therapy Development

Your Preclinical Partner for Cancer Treatment Research and Testing

Our team of experts possesses extensive experience in understanding the pathogenesis, progression, and potential therapeutic targets of a wide range of cancers. We are proficient in a variety of in vitro and in vivo cancer treatment assays, capable of evaluating the efficacy, safety, and pharmacokinetic properties of potential anti-cancer compounds, cellular therapies, and gene-editing technologies.

Our experts have significant experience in radiation biology and DNA damade response mechanisms. Additionally, Southern Research has strong immunology expertise to complement our cancer research services.

Comprehensive Services Spanning the Cancer Treatment Spectrum

We offer a comprehensive suite of preclinical cancer treatment services tailored to address the diverse challenges posed by this disease, encompassing every stage of the research process:

Cancer Cell Line Characterization and Development: We help you establish and characterize relevant cancer cell lines, providing crucial models for investigating cancer biology and evaluating therapeutic interventions.

Target Identification and Validation: We employ advanced molecular and genetic techniques to identify and validate novel therapeutic targets in a wide range of cancers, laying the foundation for effective drug discovery efforts and personalized medicine approaches.

Anti-Cancer Compound, Cellular Therapy, Biologics, and Nucleotide-Based Technology Screening and Optimization: We utilize a range of in vitro and in vivo screening assays to identify promising anti-cancer compounds, cellular therapies, and gene-editing technologies, optimizing their potency, selectivity, and safety profile.

Pharmacokinetic and Pharmacodynamic (PK/PD) & Biodistribution Studies: We determine the absorption, distribution, metabolism, and excretion (ADME) properties of potential anti-cancer compounds, cellular therapies, and gene-editing technologies, providing valuable insights into their pharmacokinetic profiles and pharmacodynamic effects in various cancer models.

Regulatory Support and IND/IDE Preparation: We guide you through the intricate regulatory landscape, ensuring compliance with FDA guidelines and facilitating the preparation of Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications.

Breast Cancer Research

Breast cancer is a complex and multifaceted disease that affects millions of people worldwide. We are proficient in a variety of in vitro and in vivo breast cancer assays, capable of evaluating the efficacy, safety, and pharmacokinetic properties of potential anti-cancer compounds, cellular therapies, and gene-editing technologies. We offer a comprehensive suite of breast cancer research services tailored to address the diverse challenges posed by this disease.

Myeloma Research

Myeloma is a type of blood cancer that develops from plasma cells. Antibodies are proteins that help the immune system fight infection. In myeloma, the plasma cells become cancerous and grow uncontrollably in the bone marrow, the spongy tissue inside bones where blood cells are made. Myeloma is a relatively rare cancer, accounting for about 1% of all cancers in the United States. We recognize that each myeloma drug candidate has unique characteristics and requirements. That’s why we take a personalized approach to preclinical research, carefully tailoring our studies to evaluate the specific challenges and opportunities of your therapeutic compound.

Colorectal Cancer Research

Colorectal cancer is a cancer of the colon or rectum. It is the third most common cancer in the United States, and the second leading cause of cancer death in both men and women.  At Southern Research, we understand the critical role that fundamental research plays in guiding preclinical and clinical studies towards the successful development of novel colorectal cancer therapies. Our team of experienced scientists is dedicated to providing comprehensive and high-quality research and testing services that help our clients advance their drug candidates to the clinic with confidence.

Pancreatic Cancer Research

Pancreatic cancer is a type of cancer that begins in the pancreas, a gland located behind the stomach in the abdomen. The pancreas plays a vital role in digestion by producing enzymes that break down food and hormones that regulate blood sugar levels. Pancreatic cancer is one of the most challenging and deadly cancers, with a five-year survival rate of around 9%. At Southern Research, we understand the urgency of finding effective treatments for pancreatic cancer, one of the most challenging and devastating malignancies. Our team of experienced scientists is dedicated to providing comprehensive and high-quality research and testing services that help our clients advance their drug candidates to the clinic with confidence.

Brain Cancer/Glioblastoma Research

Brain cancer is a broad term that encompasses a variety of tumors that arise from the brain or its lining membranes. These tumors can be classified according to their cell type, location, and behavior. Glioblastoma is the most common and aggressive type of primary brain cancer, accounting for about 45-55% of all primary brain tumors. It is characterized by rapid growth, invasiveness into surrounding brain tissue, and a dismal prognosis. We understand the unique challenges and complexities of brain cancer and glioblastoma research and testing. Our team of experienced scientists is dedicated to providing comprehensive and high-quality research and testing services that help our clients advance their drug candidates to the clinic with confidence.

 

SR-Oncology-Webinar-Graphic-Image-1

Watch Our Latest Webinar

The tumor immune microenvironment (TIME) plays a major role in tumor progression, therapy response, and ultimate prognosis. Therefore, key cells, pathways, and proteins within the TIME are being evaluated as targets for new cancer drugs. Watch as Dr. Rebecca Boohaker, our Director of Oncology, highlights progress in three drug discovery initiatives that use this interdisciplinary approach to target immune suppression in the TIME.

Watch Now
A73I7967

Accelerating the Pace of Cancer Treatment Research

By partnering with Southern Research, you gain access to a wealth of expertise, resources, and infrastructure, enabling you to focus on your core competencies while we handle the complexities of preclinical cancer treatment research and testing.

Contact Us

Our Experts

Rebecca Boohaker, Ph.D.

Director of Oncology

Corinne E.
Augelli-Szafran, Ph.D.

Vice President of Scientific Platforms

Omar Moukha-Chafiq, Ph.D.

Director of Chemistry

The Power of Collaboration

At Southern Research, we are passionate about unlocking the mysteries of cancer and contributing to the development of transformative therapies that will change the lives of millions. We are your trusted partner in addressing this global challenge, providing you with the expertise and support you need to make a profound impact on the fight against cancer.

Contact us today to discuss your preclinical cancer treatment research and testing needs, and let us help you pave the way for a future where cancer is no longer a life-threatening disease.

Southern Research News

Southern Research Selects Chief Operating Officer

May 9, 2024

May 8, 2024 Birmingham, Ala. – Harry C. Ledebur, Jr., Ph.D., is joining Southern Research as Chief Operating Officer, bringing to the role more than 25 years of experience across the pharmaceutical, biotechnology, and contract-research industry. In his new position at Southern ...
Read More

Southern Research Awarded Grant to Develop Novel Antidotes for Arsenical Poisoning

April 11, 2024

Project Aims to Deliver Safer and More Effective Treatments for Cutaneous Injuries Southern Research is pleased to announce the award of a UG3/UH3 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health (N...
Read More

Radyus Research Forges Strategic Partnership with Southern Research to Propel Life Sciences Commercialization

March 13, 2024

Radyus Research, a global drug development organization from Atlanta, Georgia, is excited to announce a pivotal strategic partnership with Southern Research, a Birmingham-based contract research organization with more than 80 years of experience in drug discovery and development. This partners...
Read More